Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ABL001 in Combination With Dasatinib, Prednisone, and Blinatumomab in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML)

NCT03595917 is registered in ClinicalTrials.gov with Marlise Luskin, MD as lead sponsor.

NCT NCT03595917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03595917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ABL001 in Combination With Dasatinib, Prednisone, and Blinatumomab in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML)
Lead sponsor
Marlise Luskin, MD
Phase
Phase 1
Overall status
Recruiting
Start date
July 24, 2018
Completion date
November 1, 2027
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, chronic myeloid leukemia (cml) in lymphoid blast crisis, philadelphia chromosome positive acute lymphoblastic leukemia ph+ all